Treatment of chronic hepatitis C

Minerva Medica

Volumn 100, Issue 6, 2009, Pages 459-465

  Bihl, F ^a   Negro, F ^a,b  

^a Division of Gastroenterology and Hepatology   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antiviral agents; Hepatitis C, chronic; Virology

Indexed keywords

CYCLOPHILIN; NITAZOXANIDE; PEGINTERFERON ALPHA; PROTEINASE; RIBAVIRIN; VIRUS RNA;

DISEASE MARKER; ERADICATION THERAPY; HEPATITIS C; HUMAN; LIVER BIOPSY; PROTEIN BINDING; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOPSY, NEEDLE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 77949794874     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Ghany MG, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-73.
2. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007;14:107-15.
3. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589-600.
4. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-14.
5. Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005;42:491-8.
6. Maylin S, Martinot-Peignoux M, Ripault MP, Moucari R, Cardoso AC et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009;29:511-7.
7. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
8. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009;49:358-63.
9. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009;150:528-40.
10. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41.
11. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009;29(Suppl 2):26-37.
12. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
13. Overbeck K, Genné D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferonalpha and ribavirin. J Hepatol 2008;49:295-8.
14. Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts. Hepatology 2008;48:383A.
15. Conjeevaram H, Burant CF, McKenna, Harsh D, Kang H, Das AK et al. A randomized, double-blind, placebo-controlled study of PPARgamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008;48:384A.
16. Romero-Gomez M, Diago M, Andrade RJ, Calleja JL, Salmeron J, Fernandez-Rodriguez CM et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naïve genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial. Hepatology 2008;48:380A.
17. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9.
18. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496-504.
19. Hassan MI, Kassim SK, Ali HS, Sayed el-DA, Khalifa A. Evaluation of nitric oxide (NO) levels in hepatitis C virus (HCV) infection: relationship to schistosomiasis and liver cirrhosis among Egyptian patients. Dis Markers 2002;18:137-42.
20. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D et al. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 2002;97:982-7.
21. Aurora R, Donlin MJ, Cannon NA, Tavis JE. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009;119:225-36.
22. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009;29:4841-51.
23. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
24. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
25. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
26. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63.
27. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
28. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
29. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D et al. HCV SPRINT-1 final results: SVR24 from a phase 2 study of boceprevir plus PEGIntronTM (peginterferon alfa2b)/ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C. J Hepatol 2009;50(Suppl 1):S4.
30. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009;49:1460-8.
31. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-62.